References
- Girouard N, Theoret G. Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis. Can J Neurosci Nurs 2008;30:18-25
- Jaber A, Bozzato GB, Vedrine L, et al. A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis. BMC Neurol 2008;8:38
- Tornatore C, Bartlett D. Tolerability of interferon beta-1b (Betaferon/Betaseron) can be significantly improved using both interferon-free needle and automated injection techniques. J Neurol 2002;249(Suppl 1):814
- Brochet B, Lemaire G, Beddiaf A. Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices. Rev Neurol (Paris) 2006;162:735-40
- Burks J. Interferon-beta1b for multiple sclerosis. Expert Rev Neurother 2005;5:153-64
- Baum K, O’Leary C, Coret Ferrer F, et al. Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b. Mult Scler 2007;13:1153-60
- Bugge J-P, Reis L. Assessment of Betaferon® Application Systems in Portugal: Patients’ Feedback [Poster]. 2007 Consortium of Multiple Sclerosis Centres Annual Meeting, Washington, Washington DC, USA, 2007
- Mayer G, Knappertz V, Kinast P. Needles: a comparison study. Med Device Technol 2009;20:30, 32-4
- Brandes DW, Callender T, Lathi E, et al. A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events. Curr Med Res Opin 2009;25:77-92
- Treadaway K, Hawker K, Racke M, et al. Factors that influence adherence with disease-modifying therapy in multiple sclerosis [P01.071]. Presented at: 58th Annual Meeting of the American Academy of Neurology, April 1--8, San Diego, CA, 2006
- Webb UH. Early interferon beta treatment in multiple sclerosis: nursing care implications of the BENEFIT study. J Neurosci Nurs 2008;40:356-61